Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

Jeffrey J. Germer, Nizar N. Zein, Mohamed A. Metwally, Tanya L. Hoskin, W. Scott Harmsen, Thomas F. Smith, Robin Patel

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

Original languageEnglish (US)
Pages (from-to)615-618
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume47
Issue number4
DOIs
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy'. Together they form a unique fingerprint.

  • Cite this